Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, Lammerts van Bueren J, Chiu C, Doshi P, Pérez-Galán P.

Haematologica. 2019 Jul 11. pii: haematol.2018.211904. doi: 10.3324/haematol.2018.211904. [Epub ahead of print]

2.

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27.

3.

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, Salaverria I, Campo E, Colomer D, Martinez A, Rymkiewicz G, Pérez-Galán P, Lopez-Guillermo A, Roué G.

Oncogene. 2018 Apr;37(14):1830-1844. doi: 10.1038/s41388-017-0111-1. Epub 2018 Jan 22.

PMID:
29353886
4.

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.

Balsas P, Esteve-Arenys A, Roldán J, Jiménez L, Rodríguez V, Valero JG, Chamorro-Jorganes A, de la Bellacasa RP, Teixidó J, Matas-Céspedes A, Moros A, Martínez A, Campo E, Sáez-Borderías A, Borrell JI, Pérez-Galán P, Colomer D, Roué G.

J Hematol Oncol. 2017 Mar 31;10(1):80. doi: 10.1186/s13045-017-0447-6.

5.

Lipidomic profile of GM95 cell death induced by Clostridium perfringens alpha-toxin.

Manni MM, Valero JG, Pérez-Cormenzana M, Cano A, Alonso C, Goñi FM.

Chem Phys Lipids. 2017 Mar;203:54-70. doi: 10.1016/j.chemphyslip.2017.01.002. Epub 2017 Jan 16.

PMID:
28104376
6.

Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity.

Orzáez M, Sancho M, Marchán S, Mondragón L, Montava R, Valero JG, Landeta O, Basañez G, Carbajo RJ, Pineda-Lucena A, Bujons J, Moure A, Messeguer A, Lagunas C, Herrero C, Pérez-Payá E.

PLoS One. 2014 Oct 20;9(10):e110979. doi: 10.1371/journal.pone.0110979. eCollection 2014.

7.

µ-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondria-mediated apoptosis.

Valero JG, Cornut-Thibaut A, Jugé R, Debaud AL, Giménez D, Gillet G, Bonnefoy-Bérard N, Salgado J, Salles G, Aouacheria A, Kucharczak J.

PLoS One. 2012;7(6):e38620. doi: 10.1371/journal.pone.0038620. Epub 2012 Jun 20.

8.

Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells.

Valero JG, Sancey L, Kucharczak J, Guillemin Y, Gimenez D, Prudent J, Gillet G, Salgado J, Coll JL, Aouacheria A.

J Cell Sci. 2011 Feb 15;124(Pt 4):556-64. doi: 10.1242/jcs.076745. Epub 2011 Jan 18.

9.

Active fragments from pro- and antiapoptotic BCL-2 proteins have distinct membrane behavior reflecting their functional divergence.

Guillemin Y, Lopez J, Gimenez D, Fuertes G, Valero JG, Blum L, Gonzalo P, Salgado J, Girard-Egrot A, Aouacheria A.

PLoS One. 2010 Feb 5;5(2):e9066. doi: 10.1371/journal.pone.0009066.

Supplemental Content

Loading ...
Support Center